找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Immunotherapies; Solid Tumors and Hem Priya Hays Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive license

[復(fù)制鏈接]
查看: 47771|回復(fù): 49
樓主
發(fā)表于 2025-3-21 20:07:59 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Cancer Immunotherapies
副標(biāo)題Solid Tumors and Hem
編輯Priya Hays
視頻videohttp://file.papertrans.cn/222/221136/221136.mp4
概述Presents the clinical scope of cancer immunotherapeutic agents for solid tumors and hematological malignancies.Examines the latest advances and their implications for clinical practice.Written and edi
叢書名稱Cancer Treatment and Research
圖書封面Titlebook: Cancer Immunotherapies; Solid Tumors and Hem Priya Hays Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive license
描述.This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells..The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes bothsolid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of c
出版日期Book 2022
關(guān)鍵詞Cancer Immunotherapy; hematological malignancies; immune checkpoint inhibitors; adoptive T cell therapi
版次1
doihttps://doi.org/10.1007/978-3-030-96376-7
isbn_softcover978-3-030-96378-1
isbn_ebook978-3-030-96376-7Series ISSN 0927-3042 Series E-ISSN 2509-8497
issn_series 0927-3042
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱Cancer Immunotherapies影響因子(影響力)




書目名稱Cancer Immunotherapies影響因子(影響力)學(xué)科排名




書目名稱Cancer Immunotherapies網(wǎng)絡(luò)公開度




書目名稱Cancer Immunotherapies網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cancer Immunotherapies被引頻次




書目名稱Cancer Immunotherapies被引頻次學(xué)科排名




書目名稱Cancer Immunotherapies年度引用




書目名稱Cancer Immunotherapies年度引用學(xué)科排名




書目名稱Cancer Immunotherapies讀者反饋




書目名稱Cancer Immunotherapies讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:18:16 | 只看該作者
板凳
發(fā)表于 2025-3-22 03:22:36 | 只看該作者
地板
發(fā)表于 2025-3-22 07:15:22 | 只看該作者
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma,efficacy and safety of CAR T cell therapy in GBM. In this review, common challenges associated with treating GBM will be discussed in addition to how CAR T cells can overcome such barriers. Additionally, emerging techniques of optimizing CAR T cell therapy for GBM will be emphasized, highlighting the prospective promise of cellular immunotherapy.
5#
發(fā)表于 2025-3-22 10:11:33 | 只看該作者
6#
發(fā)表于 2025-3-22 14:14:34 | 只看該作者
7#
發(fā)表于 2025-3-22 19:48:02 | 只看該作者
8#
發(fā)表于 2025-3-22 22:46:33 | 只看該作者
9#
發(fā)表于 2025-3-23 03:57:47 | 只看該作者
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity,rticularly with the goal of generating Th1-promoting inflammation that stokes endogenous priming of antitumor CD8. T cells, is a growing area of clinical investigation. This approach is analogous to in situ vaccination, ultimately providing a personalized antitumor response against relevant tumor as
10#
發(fā)表于 2025-3-23 05:47:12 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-23 21:46
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
来宾市| 康保县| 永昌县| 新建县| 墨江| 濉溪县| 四平市| 南溪县| 灵宝市| 庄河市| 汉沽区| 榆林市| 高青县| 曲麻莱县| 科技| 衡山县| 葵青区| 宾阳县| 晋州市| 惠州市| 陵水| 松江区| 南郑县| 阳曲县| 平远县| 金堂县| 射阳县| 绥阳县| 津南区| 乌海市| 兰考县| 新兴县| 利川市| 会同县| 罗江县| 高要市| 沈丘县| 凭祥市| 南阳市| 清丰县| 拜泉县|